We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks t... Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. Show more
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time. The conference will be held...
Nvidia (NASDAQ:NVDA) – Nvidia shares are up 1.7% in Tuesday’s pre-market, driven by Oracle‘s (NYSE:ORCL) emphasis on its importance in the artificial intelligence market. After...
- Study Did Not Meet Primary Endpoint Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 11:10 a.m. Eastern Time. A...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.51 | -2.93103448276 | 17.4 | 17.615 | 16.765 | 1074377 | 17.07434849 | CS |
4 | -1.46 | -7.95640326975 | 18.35 | 18.63 | 16.765 | 1346968 | 17.81231694 | CS |
12 | -10.29 | -37.8587196468 | 27.18 | 27.94 | 16.765 | 1783431 | 21.81756089 | CS |
26 | -6.47 | -27.6969178082 | 23.36 | 32.59 | 16.765 | 1767435 | 24.08351372 | CS |
52 | -2.75 | -14.0020366599 | 19.64 | 33.99 | 16.765 | 1687230 | 24.75848548 | CS |
156 | -4.1545 | -19.7415001544 | 21.0445 | 33.99 | 12.24 | 1669357 | 21.19438584 | CS |
260 | -6.85 | -28.8542544229 | 23.74 | 58.72 | 12.24 | 1609705 | 27.9943438 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions